Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 Junho 2023 - 6:00PM
Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company
focused on developing next-generation therapeutics to target
difficult-to-treat cancers, reported today that Pyxis Oncology’s
Compensation Committee of the Board of Directors granted restricted
stock units with respect to an aggregate of 8,310 shares of Pyxis
Oncology’s common stock and stock options to purchase an aggregate
of 10,388 shares of Pyxis Oncology’s common stock to three newly
hired employees. The awards were granted under the Pyxis Oncology,
Inc. 2022 Inducement Plan with a grant date of June 30, 2023, as an
inducement material to the new employee entering employment with
Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units and stock options vest over four
years, with 25% vesting on the first anniversary of the vesting
commencement date for each employee and the remaining shares
vesting monthly over the 36-month period thereafter, subject to
continued employment with the Company through the applicable
vesting dates. The stock options have a ten-year term and an
exercise price of $2.56, the closing price of Pyxis Oncology’s
common stock as reported by Nasdaq on June 30, 2023.
Pyxis Oncology is providing this information in accordance with
Nasdaq Listing Rule 5635(c)(4).
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical-stage company focused on
defeating difficult-to-treat cancers. The company is efficiently
building next-generation therapeutics that hold the potential for
mono and combination therapies. Pyxis Oncology’s therapeutic
candidates are designed to directly kill tumor cells and to address
the underlying pathologies created by cancer that enable its
uncontrollable proliferation and immune evasion. Pyxis Oncology’s
antibody-drug conjugates (ADCs) and immuno-oncology (IO) programs
employ novel and emerging strategies to target a broad range of
solid tumors resistant to current standards of care. To learn more,
visit www.pyxisoncology.com or follow us
on Twitter and LinkedIn.
Pyxis Oncology ContactJennifer Davis
Ruffir@pyxisoncology.com
Media ContactJason Braco,
Ph.D.jbraco@lifescicomms.com
Pyxis Oncology (NASDAQ:PYXS)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Pyxis Oncology (NASDAQ:PYXS)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024